A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Incyte Corporation
Kiadis Pharma
M.D. Anderson Cancer Center
Children's Oncology Group
Dana-Farber Cancer Institute
Fred Hutchinson Cancer Center
Vanderbilt-Ingram Cancer Center
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital